Passing Higher Raw Material and Transportation Costs Through to Product Prices
First written in FY2023-Q2. 5 of 10 entries say "Advanced", first in FY2024-Q1. Latest entry: 2026-08-06.
39 other companies' latest entry also says "Advanced".
- 2026-08-06AdvancedEarnings
「The clinical laboratory business increased revenue due to growth in routine testing, higher testing revenue in the genetics field as a growth initiative, and progress in optimizing selling prices.」
Progress in optimizing selling prices, together with higher testing revenue in the genetics field, was identified as a factor behind the increase in revenue in the clinical laboratory business. - FY2026AdvancedAnnual report
「The pathology business posted higher earnings, driven by the effects of price revisions, cost reductions from optimizing production sites, and the recognition of other income following the reclassification of an affiliated company.」
The effects of price revisions, production-site optimization and cost reductions were reflected in full-year earnings growth in the pathology business. - FY2026-H1AdvancedAnnual report
「Profit increased substantially, supported by strong performance in the BGM business in developed countries, margin improvement from revenue-enhancement and unit-price improvement measures, the cost-saving effects of previous restructuring, and lower depreciation and amortization expenses, among other factors.」
The effects of initiatives to increase unit prices and structural reforms and cost reductions materialised as improved margins and substantial profit growth in the BGM business. - FY2025AdvancedAnnual report
「The pathology business posted higher profit as a result of increased revenue, cost-reduction measures such as lower transportation costs, and improved margins supported by the effects of past organizational streamlining, among other factors.」
The effects of lower transportation costs, cost reductions and organisational streamlining materialised as improved margins and higher full-year profit in the Pathology business. - FY2024RestatedAnnual report
「In the Biomedica business, the effects of price revisions were insufficient to absorb higher costs associated with inflation and other factors.」
Although the company continues to implement price revisions, it was unable to fully absorb higher costs associated with inflation. - FY2024-Q3RestatedAnnual report
「The decline in Biomedica revenue was mainly due to the contraction of special demand for ultra-low-temperature freezers used to store mRNA vaccines in the research and medical support equipment sector. Meanwhile, sales to general-demand customers in the sector, excluding special demand, increased due in part to price revisions and favourable foreign exchange effects.」
Although sales to general-demand customers increased due to the effects of price revisions, the increase was not enough to offset the revenue decline resulting from the contraction of special demand. - FY2024-Q2RestatedAnnual report
「Although measures such as price increases and cost reductions have produced some improvement in performance,」
The company continues to implement price increases and cost reductions in the Pathology business and other areas, and explains that these measures have produced some improvement in performance. - FY2024-Q1AdvancedAnnual report
「In the Biomedica business, sales in the research and medical support equipment field declined year on year as exceptional demand for ultra-low-temperature freezers used to store mRNA vaccines contracted. Excluding exceptional demand, however, sales generated by general demand increased due to favorable effects from price revisions and foreign exchange movements.」
The company explains that sales to general-demand customers, excluding special demand, increased due to the effects of price revisions, demonstrating that its response to product pricing translated into actual results. - FY2023-Q3RestatedAnnual report
「The impact of higher raw material and transportation costs is being mitigated through cost-cutting initiatives and passing the increases through to product prices.」
The company continues to address higher raw material and transportation costs through cost reductions and passing the increases through to product prices. - FY2023-Q2First statedAnnual report
「The company is promoting the pass-through of higher costs into product prices, including in the Biomedica business, but profit declined due in part to the impact of higher raw material and transportation costs.」
To address higher raw material and transportation costs, the company is promoting price pass-through for products, including those in the Biomedica business.